ArticleThe World Allergy Organization journal2026
High degree of remission in pediatric severe asthma patients treated with biologics in a real-world setting.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asthma is the most common chronic disease in childhood and although many children with asthma achieve disease control with low- to medium-dose inhaled corticosteroids, 2-10% have severe asthma (SA). Biologics have been available for treatment in adults and adolescents for almost twenty years, and currently 5 biologic therapies have been approved by regulatory agencies for SA in children and/or adolescents. Objective: To describe the evolution and remission rate of pediatric SA patients on biologics, including after switch of biologic. Methods: A retrospective observational study was conducted January 2023 to January 2024 in SA children (6-18 years) in a tertiary care hospital. American Thoracic Society/European Respiratory Society (ATS/ERS) criteria classified asthma as severe. Patients who started biologic therapy, or who switched from a previous biologic, were included. Index date is the timepoint at which biologic therapy was started or switched. We compare clinical and biomarker (fractional exhaled nitric oxide, blood eosinophil count [BEC], IgE) data from 12 months pre- with 12 months postindex- date. Results: Sixty children were included (mean age 14.1 ± 3.2 years); 34/60 (56%) female. Our 46 biologic-naïve patients received omalizumab in 21/46 (46%), dupilumab in 23/46 (50%), and mepolizumab in 2 (4%). Fourteen switchers (23%), who presented incomplete improvement on their first biologic, were changed to a second/third biologic including benralizumab and tezepelumab. Our children experienced an average of 2.4 severe exacerbations 12 months pre-index date. Twelve months post-index-date, no child experienced severe exacerbations and 98% (59/60) reached complete, 4- parameter, clinical remission plus a significant reduction of all biomarkers. Conclusion: The use of biologic therapies in pediatric patients with SA allowed for adequate disease control. With correct biologic selection or timely switch when incomplete response, clinical remission, normalization of lung function and a reduction in ICS daily dose was achieved in a very high percentage. Moreover, controlling asthma enables allergen-specific immunotherapy for children with allergic SA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.